Cowen initiates Repligen stock with Buy rating, $200 target
TD Cowen began coverage on Repligen Corporation (NASDAQ:RGEN), a prominent bioprocessing company, with a Buy rating and a price target set at $200. The firm highlighted Repligen's strong position for ...
10x Genomics price target lowered to $18 from $19 at Barclays
Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...
Bruker price target lowered to $65 from $69 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...